Back to Journals » International Journal of Nanomedicine » Volume 6

Novel PEG-graft-PLA nanoparticles with the potential for encapsulation and controlled release of hydrophobic and hydrophilic medications in aqueous medium

Authors Wang B , Jiang W, Yan H, Zhang X, Li Yang, Deng L, Singh GK, Pan J 

Published 7 July 2011 Volume 2011:6 Pages 1443—1451


Review by Single anonymous peer review

Peer reviewer comments 4

Bin Wang1,2, Weimin Jiang1,2, Hao Yan1,2, Xiaoxi Zhang1,2, Li Yang1,2, Lihong Deng1,2, Gurinder K Singh1,2, Jun Pan1,2
1Bioengineering College, Chongqing University, Chongqing, People’s Republic of China; 2Key Laboratory of Biorheological Science and Technology (Chongqing University), Ministry of Education, Chongqing, People’s Republic of China
The first two authors contributed equally to this work

Abstract: This study concerns the encapsulation and controlled release of both hydrophobic and hydrophilic medications with one polymer, which are delivered together as a combined therapy to treat diseased tissue. To test our hypothesis that the novel PEG-graft-PLA (PEG, polyethylene glycol; PLA, polylactic acid) can deliver both the hydrophobic and hydrophilic medications on account of its amphiphility, charge, and graft structure, PEG-graft-PLA (molecular weight of PEG = 1900) with very low critical micelle concentration was synthesized. One hydrophilic (insulin) and one hydrophobic (naproxen) model medication were loaded in separately during its self-assembly in aqueous solution. The resulting nanoparticles (NPs) were narrowly distributed and spherical, with average particle size around 200 nm, zeta potential >—10 mV, and encapsulation efficiency >50%. The NPs realized controlled release of insulin and naproxen for over 24 and 160 hours, respectively. Specifically, the bioactivity of the insulin released from the NPs was maintained. Owing to encapsulation, both for hydrophobic and hydrophilic medicines, and NPs obtained with similar size and zeta potential, as well as maintenance of bioactivity of loaded protein, we expect the applications of PEG-graft-PLA NPs in combination therapy.

Keywords: NPs, insulin, naproxen, controlled release, combination therapy

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.